A Phase 1b/2 Open-label Study of IMU-131 HER2/Neu Peptide Vaccine Plus Cisplatin and Either 5-Fluorouracil or Capecitabine Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
Phase of Trial: Phase I/II
Latest Information Update: 25 Jul 2017
At a glance
- Drugs IMU 131 (Primary) ; Capecitabine; Cisplatin; Fluorouracil
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Imugene
- 19 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
- 10 Jun 2017 Biomarkers information updated
- 03 Nov 2016 Status changed from not yet recruiting to recruiting.